T4 100 - Pharmaceutical Grade

Synthroid, the brand name for levothyroxine sodium, was launched in 1955 and became a dominant thyroid hormone therapy in the U.S. Marketed by Flint Laboratories, the drug gained a monopoly position until generic competition surged in the 1980s. Flint funded a study to validate Synthroid’s superiority, but when results proved generics were equally effective, the company attempted to suppress publication. A court ultimately ordered the study’s release in 1997, followed by a class-action lawsuit and a substantial settlement.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about T4 100 by Pharmaceutical Grade, consult with your doctor or healthcare professional.